Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Jazz Pharmaceuticals plc - Ordinary Shares
(NQ:
JAZZ
)
165.00
-0.50 (-0.30%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Jazz Pharmaceuticals plc - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
3 Cash-Producing Stocks We Think Twice About
February 05, 2026
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Via
StockStory
$100 Million Exit: Why One Fund Walked Away From a Chinese E-Commerce Stock Up 24%
↗
January 29, 2026
Vipshop Holdings is a major Chinese e-commerce retailer specializing in branded discount sales for value-focused consumers.
Via
The Motley Fool
Topics
Economy
This Bank Stock Just Saw a $24 Million Fund Sale, but Here's Why It's Still a Top Holding
↗
January 29, 2026
Popular, Inc. offers retail and commercial banking services across Puerto Rico, the U.S., and the British Virgin Islands.
Via
The Motley Fool
Topics
Credit Cards
ETFs
Earnings Scheduled For November 5, 2025
↗
November 05, 2025
Via
Benzinga
Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed?
↗
January 27, 2026
Some investors haven't gotten answers to their questions about the biotech stock's past and future.
Via
The Motley Fool
Topics
Initial Public Offering
Intellectual Property
3 of Wall Street’s Favorite Stocks We Think Twice About
January 26, 2026
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...
Via
StockStory
3 Small-Cap Stocks That Fall Short
January 12, 2026
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...
Via
StockStory
Topics
Electric Vehicles
Reflecting On Pharmaceuticals Stocks’ Q3 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ)
December 28, 2025
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the pharmaceuticals stocks, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
3 Mid-Cap Stocks with Warning Signs
December 22, 2025
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract...
Via
StockStory
3 Reasons JAZZ is Risky and 1 Stock to Buy Instead
December 17, 2025
The past six months have been a windfall for Jazz Pharmaceuticals’s shareholders. The company’s stock price has jumped 50.6%, hitting $163 per share. This was partly due to its solid quarterly results,...
Via
StockStory
Topics
Bankruptcy
3 Value Stocks We’re Skeptical Of
December 11, 2025
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...
Via
StockStory
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?
↗
December 09, 2025
A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters.
Via
The Motley Fool
Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow?
↗
December 09, 2025
Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down.
Via
The Motley Fool
Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets
↗
December 09, 2025
A biotech specialist doubled down on Dyne ahead of a clinical readout that drew up investor fanfare — and the timing may be the entire story.
Via
The Motley Fool
Topics
Regulatory Compliance
3 Healthcare Stocks We’re Skeptical Of
December 02, 2025
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand,...
Via
StockStory
Topics
Stocks
Stocks making big moves yesterday: Dycom, ACV Auctions, Jazz Pharmaceuticals, Coinbase, and Gibraltar
November 18, 2025
Check out the companies making headlines yesterday:
Via
StockStory
3 of Wall Street’s Favorite Stocks Walking a Fine Line
November 17, 2025
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...
Via
StockStory
Jazz Pharmaceuticals Stock Rallies On Positive Phase 3 Trial Results for Ziihera In Advanced Gastroesophageal Cancer
↗
November 17, 2025
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) shares are popping on Monday following the company's positive results of its Phase 3 HERIZON-GEA-01 trial, which assessed Ziihera in combination with...
Via
Benzinga
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans
↗
November 17, 2025
Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings and guideline submissions.
Via
Benzinga
Why Is Jazz Pharmaceuticals (JAZZ) Stock Soaring Today
November 17, 2025
Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 18.3% in the morning session after the company announced positive top-line results from its Phase 3 HERIZON-GEA-01 trial for its...
Via
StockStory
Topics
Artificial Intelligence
Stocks
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday
↗
November 17, 2025
Via
Benzinga
The market is filled with gapping stocks in Monday's session.
↗
November 17, 2025
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.
Via
Chartmill
Mixed Signals Point to Cautious Open for U.S. Markets as Tech Shines Amidst Economic Data Delays
November 17, 2025
U.S. equity futures are signaling a mixed but largely cautious start to the trading day on November 17, 2025, with technology stocks once again taking the lead, while broader indices like the Dow Jones...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Electric Vehicles
Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer
↗
November 17, 2025
Shares of Jazz Pharmaceuticals and Zymeworks catapulted Monday on positive test results for a gastric cancer drug.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
November 17, 2025
Via
Benzinga
The Top 5 Analyst Questions From Jazz Pharmaceuticals’s Q3 Earnings Call
November 12, 2025
Jazz Pharmaceuticals delivered a quarter that exceeded Wall Street’s expectations, with management attributing results to robust demand for Xywav and Epidiolex, as well as the swift and successful...
Via
StockStory
Topics
Earnings
Pfizer, Amneal, Jazz Pharmaceuticals, BD, and DaVita Shares Skyrocket, What You Need To Know
November 11, 2025
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid...
Via
StockStory
Topics
Artificial Intelligence
Stocks
JAZZ Q3 Deep Dive: New Drug Launches and Portfolio Expansion Drive Strong Results
November 06, 2025
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 6.7% year on year to $1.13 billion. The company expects the...
Via
StockStory
Jazz Pharma (JAZZ) Earnings Call Transcript
↗
November 05, 2025
Jazz Pharma (JAZZ) Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Jazz Pharmaceuticals’s (NASDAQ:JAZZ) Q3: Beats On Revenue
November 05, 2025
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 6.7% year on year to $1.13 billion. The company expects the full...
Via
StockStory
Topics
Supply Chain
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today